Uncategorized
Oyster Point Announces Positive Results From Two Separate Phase 2b Clinical Trials of the Company’s Investigational Treatments for Dry Eye Disease
PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma, Inc., today announced results from the ONSET and RAINIER studies, two separate Phase 2b clinical trials evaluating the company’s novel therapies for the treatment of Dry Eye Disease (DED). Both studies, being presented tomorrow at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrated improvement in Schirmer’s score and multiple measures of eye dryness symptoms. “The results announced today demonstrate the potential clin